Logo

Mixing Genomics and Proteomics to Fight Cancer

Jul 09, 2008

Dana-Farber Cancer Institute's Kimberly Stegmaier led a study published yesterday in PNAS that uses a "signature-based screening approach" to identify hits in neuroblastoma treatment. Her team used gene expression analysis to screen a small molecule library, and the top hit was all-trans-retinoic acid. They found that by combining this with an HDAC inhibitor increased neuroblastoma differentiation, which is typically abnormal in this pediatric cancer.

Breaking News
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.